$45.5m market cap

$0.19 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and ClyraGuard, a disinfectant for healthcare workers. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

BioLargo reported $666,000 in total Q320 sales (+24.7% y-o-y), a new record, a $1.9m operating loss (flat year-on-year) and a $2.39m net loss (from $3.89m in Q319). It had $356,000 in Q320 sales from ONM Environmental, down 10% from Q319, but the division recovered significantly since the start of the pandemic (up 19% from Q120). Sequentially, companywide revenue growth was up 56% over Q220, a strong bounce back from COVID-19 disruptions, and total sales are up 15% for 9M20 to $1.52m. BioLargo also announced that BioLargo Water is ready for commercial operations and we expect to see an increased sales effort.

Register to receive research on BioLargo as it is published
Share price graph
Price performance
Actual 5.7 33.5 16.0
Relative* 0.7 22.8 (22.6)
52-week high/low US$0.2/US$0.1
*% relative to local index
Key management
Dennis Calvert President & CEO